In 2016 it was the medication that gave the biggest cost to the system by the judicial way, accounting to 625 million reais (about US$ 178 million at the time) to treat 364 patients, but it was second when counting all the system regular medications, the biggest cost being sofosbuvir. Brazil's supreme court ruled in April 2018 to break the patent of Soliris in Brazil, enabling it to be produced locally.
In 2016, the medication that incurred the highest cost to the system through legal means, amounting to 625 million reais (approximately US$ 178 million at the time), was used to treat 364 patients, but it ranked second when considering all regular medications within the system. The Brazilian Supreme Court ruled in April 2018 to invalidate the patent of Soliris in Brazil, allowing for its production locally.